ADM Tronics Reports First Quarter of Fiscal Year 2026 Results

Rhea-AI Summary

ADM Tronics (OTCQB:ADMT) reported strong Q1 FY2026 results with revenues reaching $973,675, marking a 13.5% increase from the same period last year. The company's electronics segment led growth with a 25% increase, while the chemical segment grew by 5%. Net income rose to $327,634 from $272,168 year-over-year.

The company continues development of its medical Sonotron® device for human pain treatment, planning an FDA 510(k) submission. This non-invasive therapy uses pulsed radio frequency for treating chronic and acute musculoskeletal conditions. ADMT has already launched the Vet-Sonotron® for veterinary applications and is seeking distributors for animal markets.

Positive

• Revenue increased by 13.5% to $973,675 year-over-year
• Electronics segment showed strong 25% revenue growth
• Chemical segment revenue grew by 5%
• Net income increased to $327,634 from $272,168 year-over-year
• Other income doubled to $219,900 from $108,387

Negative

• Engineering segment revenue declined by 2%
• Income from operations decreased to $109,234 from $164,281
• Gross profit declined to $481,293 from $520,903
• Operating expenses increased to $372,059 from $356,622

NORTHVALE, NJ / ACCESS Newswire / August 19, 2025 / ADM Tronics Unlimited, Inc. (OTCQB:ADMT), a technology-based developer and manufacturer of innovative technologies and products, announces results for its first fiscal quarter ended June 30, 2025 of Fiscal Year 2025.

The upward trend in revenues, as reported in the Company's Annual 10-K Report for the fiscal year ended March 31, 2025, continues for this first fiscal quarter ended June 30, 2025 of the fiscal year ended March 31, 2026, ADMT had an increase of over 13% in revenues for the quarter ended June 30, 2025, as compared to the same period last year. ADMT's increase in revenues for the quarter ended June 30, 2025 was primarily due to an increase in revenues of over 25% in its electronics segment coupled with an increase of approximately 5% in the chemical segment, offset by a reduction of 2% in engineering segment revenues as compared to the same period last year. Income from operations was $109,234 for the quarter ended June 30, 2025 as compared to $164,281 for the quarter ended June 30, 2024 an increase of approximately 8% offset by a decrease of approximately 2% in research and development. Net income was $327,634 for the quarter ended June 30, 2025 as compared to $272,168 for the same period last year.

During the quarter ended June 30, 2025, ADMT continued research and development efforts on the medical version of the Sonotron^® for use on humans where the need for effective pain treatment without the use of drugs or opioids is very large and unmet. As previously reported, this non-invasive therapy technology utilizes pulsed radio frequency output for the treatment of chronic and acute musculoskeletal pain conditions such as osteoarthritis, tendonitis, and other conditions and diseases. The company plans on pursuing a 510(k) submission to the FDA when development of the human medical version is completed. The Company commercially introduced the Vet-Sonotron^®, a professional veterinary version of this technology for treatment of animals, and continues to seek national or regional distributors for sales and marketing to the small animal and equine veterinary markets.

Revenues for the quarter ended June 30, 2025, were $973,675 as compared to $857,845 for the same period last year, an increase of 13.5%. Income from operations for June 30, 2025 was $109,234 as compared to $164,281 for the same period last year. Complete financial results are available in the Company's Quarterly Report on Form 10Q for June 30, 2025, available at www.sec.gov.

Financial Highlights

		Three Months Ended				Three Months Ended
		June 30, 2025				June 30, 2024
Net Revenues		$	973,675			$	857,845
Cost of sales			492,382				336,942
Gross Profit			481,293				520,903
Operating expenses:
Research and development			125,589				127,993
Selling, general and administrative			246,470				228,629
Total operating expenses			372,059				356,622
Income from operations			109,234				164,281
Total other income			219,900				108,387
Income before provision for taxes			329,134				272,668
Total provision for income taxes			1,500				500
Net income		$	327,634			$	272,168
Basic and diluted earnings (loss) per common share		$	0.00			$	0.00
Weighted average shares of common stock outstanding - basic and diluted			67,588,492				67,588,492

About ADMT

ADMT is a diversified, technology-based developer and manufacturer of innovative technologies and products. Its core competency is its ability to conceptualize a technology, bring it through development, into manufacturing and commercialization, all in-house. ADMT has three areas of activity: Proprietary Electronic Medical Devices; Design, Engineering, Regulatory and Manufacturing Services; and, Eco-Friendly, Safe, Water-Based Formulations. The Company's headquarters, laboratories, and FDA-Registered medical device manufacturing operations are located in Northvale, NJ. ADMT's multi-disciplinary team of engineers, researchers and technologists utilize advanced technology infrastructure, for the research, development and commercialization of diversified technologies. Additional information is available at admtronics.com

ADMT welcomes inquiries for its electronics and medical device contract engineering and manufacturing services at www.admteng.com.

To receive ADMT email updates, complete form at https://admtronics.com/investor-relations/

Sonotron^® is a registered trademark of ADM Tronics Unlimited, Inc. vet-sonotron.com

Except for historical information contained herein, the matters set forth in this news release are "forward-looking" statements (as defined in the Private Securities Litigation Reform Act of 1995), including statements regarding future revenue growth and performance. Although ADMT believes the expectations reflected in such forward-looking statements are based upon reasonable assumptions, there can be no assurance that its expectations will be realized. Forward-looking statements involve risks and uncertainties that could cause actual results to differ materially from expectations. Factors that could contribute to such differences include those described from time to time in ADMT's filings with the SEC, news releases and other communications. The Company assumes no obligation to update the information contained in this news release.

Contact: Andre' DiMino 201-767-6040, andre@admtronics.com

SOURCE: ADM Tronics Unlimited Inc.

View the original press release on ACCESS Newswire

FAQ

What were ADMT's Q1 FY2026 revenue and earnings results?

ADMT reported Q1 FY2026 revenue of $973,675, up 13.5% year-over-year, and net income of $327,634, compared to $272,168 in the same period last year.

How did ADMT's different business segments perform in Q1 2026?

The electronics segment grew 25%, chemical segment increased 5%, while the engineering segment declined 2% compared to the same period last year.

What is the status of ADMT's Sonotron medical device development?

ADMT is developing the medical version of Sonotron® for human pain treatment and plans to pursue an FDA 510(k) submission upon completion. They have already launched the Vet-Sonotron® for veterinary applications.

What was ADMT's operating income for Q1 FY2026?

ADMT's income from operations was $109,234 for Q1 FY2026, compared to $164,281 in the same period last year.

How much did ADMT's operating expenses increase in Q1 2026?

Total operating expenses increased to $372,059 from $356,622 in the previous year, with selling, general and administrative expenses rising to $246,470.